Sanofi and GSK make timely entrance to Europe's COVID-19 booster vaccine battle

11 November 2022
vaccine_shot_jab_booster_big

There is a new COVID-19 booster vaccine in town, just in time for Europe’s fall and winter season.

While they may not have reached market with a vaccine at the height of the pandemic to compete with jabs from the likes of Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), AstraZeneca (LSE: AZN) and Moderna (Nasdaq: MRNA), European pharma heavyweights Sanofi (Euronext: SAN) and GSK (LSE: GSK) have got there with a booster just in time for Europe’s upcoming colder months.

Their vaccine, VidPrevtyn Beta, is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe and was developed with US government funding. The approval was expected following a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology